Total Payments
$149,601
2024 Payments
$32,627
Companies
11
Transactions
124
Payment Breakdown by Category
Other$108,140 (72.3%)
Consulting$35,110 (23.5%)
Travel$3,306 (2.2%)
Food & Beverage$2,961 (2.0%)
Education$83.96 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $98,540 | 44 | 65.9% |
| Consulting Fee | $35,110 | 15 | 23.5% |
| Honoraria | $9,600 | 5 | 6.4% |
| Travel and Lodging | $3,306 | 16 | 2.2% |
| Food and Beverage | $2,961 | 38 | 2.0% |
| Education | $83.96 | 6 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $103,368 | 77 | $0 (2024) |
| Shire North American Group Inc | $16,239 | 15 | $0 (2019) |
| Alexion Pharmaceuticals, Inc. | $12,201 | 12 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $9,586 | 6 | $0 (2023) |
| Ultragenyx Pharmaceutical Inc. | $3,230 | 2 | $0 (2021) |
| Horizon Therapeutics plc | $2,379 | 3 | $0 (2019) |
| Amicus Therapeutics, Inc. | $2,200 | 1 | $0 (2021) |
| BioMarin Pharmaceutical Inc. | $299.73 | 4 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $56.35 | 1 | $0 (2021) |
| PFIZER INC. | $35.33 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $32,627 | 12 | GENZYME CORPORATION ($32,627) |
| 2023 | $24,175 | 16 | GENZYME CORPORATION ($21,764) |
| 2022 | $21,593 | 17 | GENZYME CORPORATION ($20,472) |
| 2021 | $13,271 | 9 | GENZYME CORPORATION ($5,685) |
| 2020 | $8,654 | 3 | Takeda Pharmaceuticals U.S.A., Inc. ($5,075) |
| 2019 | $12,140 | 17 | GENZYME CORPORATION ($9,728) |
| 2018 | $15,549 | 19 | Alexion Pharmaceuticals, Inc. ($7,136) |
| 2017 | $21,591 | 31 | Shire North American Group Inc ($12,791) |
All Payment Transactions
124 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,048.00 | General |
| 10/23/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $42.29 | General |
| 10/19/2024 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,376.00 | General |
| Category: Genetic Disease | ||||||
| 08/01/2024 | GENZYME CORPORATION | CEREZYME (Biological), CERDELGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,352.00 | General |
| Category: Genetic Disease | ||||||
| 07/30/2024 | GENZYME CORPORATION | CERDELGA (Drug), CEREZYME | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,816.00 | General |
| Category: Genetic Disease | ||||||
| 07/25/2024 | GENZYME CORPORATION | XENPOZYME (Biological) | Food and Beverage | In-kind items and services | $120.29 | General |
| Category: Genetic Disease | ||||||
| 06/02/2024 | GENZYME CORPORATION | CERDELGA (Drug), CEREZYME | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,152.00 | General |
| Category: Genetic Disease | ||||||
| 06/01/2024 | GENZYME CORPORATION | CEREZYME (Biological), CERDELGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,352.00 | General |
| Category: Genetic Disease | ||||||
| 03/09/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,376.00 | General |
| Category: Genetic Disease | ||||||
| 03/09/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Food and Beverage | In-kind items and services | $80.83 | General |
| Category: Genetic Disease | ||||||
| 02/20/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,584.00 | General |
| Category: Genetic Disease | ||||||
| 02/15/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,328.00 | General |
| Category: Genetic Disease | ||||||
| 12/05/2023 | GENZYME CORPORATION | CERDELGA (Drug) | Consulting Fee | Cash or cash equivalent | $2,048.00 | General |
| Category: Genetic Disease | ||||||
| 12/03/2023 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,826.00 | General |
| Category: Genetic Disease | ||||||
| 11/15/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 11/09/2023 | GENZYME CORPORATION | CERDELGA (Drug), CEREZYME | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,708.00 | General |
| Category: Genetic Disease | ||||||
| 10/25/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $24.42 | General |
| 10/18/2023 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $471.00 | General |
| 10/12/2023 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,649.00 | General |
| 08/08/2023 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,217.50 | General |
| Category: Genetic Disease | ||||||
| 06/27/2023 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,826.00 | General |
| 06/27/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $103.11 | General |
| 05/18/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $45.23 | General |
| 05/02/2023 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,533.00 | General |
| 03/14/2023 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,533.00 | General |
About Dr. Helio Pedro, M.D
Dr. Helio Pedro, M.D is a Internal Medicine healthcare provider based in Newark, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1215983382.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Helio Pedro, M.D has received a total of $149,601 in payments from pharmaceutical and medical device companies, with $32,627 received in 2024. These payments were reported across 124 transactions from 11 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($98,540).
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Clinical Genetics (M.D.), Clinical Biochemical Genetics
- Location Newark, NJ
- Active Since 05/26/2006
- Last Updated 09/11/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1215983382
Products in Payments
- FABRAZYME (Biological) $18,216
- CERDELGA (Drug) $17,526
- XENPOZYME (Biological) $17,318
- VPRIV (Biological) $17,164
- CEREZYME (Biological) $8,704
- Strensiq (Drug) $7,986
- LUMIZYME (Drug) $6,254
- Dojolvi (Drug) $3,200
- RAVICTI (Drug) $2,379
- CEREZYME (Drug) $2,359
- NO PRODUCT DISCUSSED (Drug) $2,302
- NEXVIAZYME (Biological) $1,551
- STRENSIQ (Biological) $1,025
- FABRAZYME (Drug) $997.50
- Kanuma (Drug) $914.58
- LUMIZYME (Biological) $706.50
- Vimizim (Biological) $161.23
- Naglazyme (Biological) $43.50
- ELELYSO (Drug) $35.33
- (820) Cholbam (Drug) $6.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Newark
Marc Cohen, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Seth Ivins, Md, MD
Internal Medicine — Payments: $459,110
Internal Medicine $459,110
Tabassum Salam, Md, MD
Internal Medicine — Payments: $74,050
Internal Medicine $74,050
Dr. Jamil Shah, Md, MD
Internal Medicine — Payments: $53,152
Internal Medicine $53,152
Dr. Christina Migliore, M.d, M.D
Internal Medicine — Payments: $33,681
Internal Medicine $33,681
Sean Dikdan, M.d., M.p.h, M.D., M.P.H
Internal Medicine — Payments: $32,386
Internal Medicine $32,386